Badar M Mian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3208868/publications.pdf

Version: 2024-02-01

1306789 887659 24 510 7 17 citations g-index h-index papers 27 27 27 810 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Reply by Authors. Journal of Urology, 2022, 207, 981-981.	0.2	O
2	Interventions to Reduce Opioid Prescriptions following Urological Surgery: A Systematic Review and Meta-Analysis. Journal of Urology, 2022, 207, 969-981.	0.2	5
3	Management of urologic cancers during the pandemic and potential impact of treatment deferrals on outcomes. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 258-267.	0.8	13
4	Impact of Enhanced Recovery after Surgery Protocols on Opioid Prescriptions at Discharge after Major Urological Cancer Surgery. Urology Practice, 2021, 8, 270-276.	0.2	5
5	Rationale and protocol for randomized study of transrectal and transperineal prostate biopsy efficacy and complications (ProBE-PC study). Prostate Cancer and Prostatic Diseases, 2021, 24, 688-696.	2.0	9
6	A rare case of urachal inflammatory myofibroblastic tumor. Urology Case Reports, 2021, 36, 101575.	0.1	O
7	Distinct mutational status in GATA3-Positive clear cell adenocarcinoma of the urinary tract: A CASE report. Urology Case Reports, 2021, 39, 101793.	0.1	1
8	Genitourinary cancer management during a severe pandemic: Utility of rapid communication tools and evidenceâ€based guidelines. BJUI Compass, 2020, 1, 45-59.	0.7	6
9	Current and emerging trends in prostate cancer immunotherapy. Asian Journal of Andrology, 2019, 21, 6.	0.8	5
10	TGF- $\hat{l}^21/p53$ signaling in renal fibrogenesis. Cellular Signalling, 2018, 43, 1-10.	1.7	110
10	TGF-β1/p53 signaling in renal fibrogenesis. Cellular Signalling, 2018, 43, 1-10. Validation of a new diagnostic platform for prostate cancer using expression profiling of small non-coding RNAs Journal of Clinical Oncology, 2018, 36, e24151-e24151.	0.8	0
	Validation of a new diagnostic platform for prostate cancer using expression profiling of small		
11	Validation of a new diagnostic platform for prostate cancer using expression profiling of small non-coding RNAs Journal of Clinical Oncology, 2018, 36, e24151-e24151. Novel platform for monitoring bladder cancer recurrence using expression analysis of small	0.8	0
11 12	Validation of a new diagnostic platform for prostate cancer using expression profiling of small non-coding RNAs Journal of Clinical Oncology, 2018, 36, e24151-e24151. Novel platform for monitoring bladder cancer recurrence using expression analysis of small non-coding RNAs Journal of Clinical Oncology, 2018, 36, 12070-12070. Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomedicine:	0.8	0
11 12 13	Validation of a new diagnostic platform for prostate cancer using expression profiling of small non-coding RNAs Journal of Clinical Oncology, 2018, 36, e24151-e24151. Novel platform for monitoring bladder cancer recurrence using expression analysis of small non-coding RNAs Journal of Clinical Oncology, 2018, 36, 12070-12070. Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 263-273. Comprehensive genomic profiling of relapsed and refractory small cell neuroendocrine carcinoma of	0.8	0 0 43
11 12 13	Validation of a new diagnostic platform for prostate cancer using expression profiling of small non-coding RNAs Journal of Clinical Oncology, 2018, 36, e24151-e24151. Novel platform for monitoring bladder cancer recurrence using expression analysis of small non-coding RNAs Journal of Clinical Oncology, 2018, 36, 12070-12070. Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 263-273. Comprehensive genomic profiling of relapsed and refractory small cell neuroendocrine carcinoma of the urinary bladder Journal of Clinical Oncology, 2017, 35, 350-350. Comprehensive genomic profiling of urethral cancer to reveal distinctive features compared to	0.8 0.8 1.7	0 0 43 3
11 12 13 14	Validation of a new diagnostic platform for prostate cancer using expression profiling of small non-coding RNAs Journal of Clinical Oncology, 2018, 36, e24151-e24151. Novel platform for monitoring bladder cancer recurrence using expression analysis of small non-coding RNAs Journal of Clinical Oncology, 2018, 36, 12070-12070. Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 263-273. Comprehensive genomic profiling of relapsed and refractory small cell neuroendocrine carcinoma of the urinary bladder Journal of Clinical Oncology, 2017, 35, 350-350. Comprehensive genomic profiling of urethral cancer to reveal distinctive features compared to bladder cancer Journal of Clinical Oncology, 2017, 35, 429-429. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer, 2016, 122,	0.8 0.8 1.7 0.8	0 0 43 3

#	Article	IF	CITATIONS
19	Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate Journal of Clinical Oncology, 2016, 34, 187-187.	0.8	1
20	Comprehensive genomic profiling of urothelial carcinoma of the kidney and ureter: Comparison with urothelial carcinoma of the bladder and impact on potential for targeted therapy selection Journal of Clinical Oncology, 2016, 34, 371-371.	0.8	0
21	Risk calculators and updated tools to select and plan a repeat biopsy for prostate cancer detection. Asian Journal of Andrology, 2015, 17, 864.	0.8	2
22	Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urology, 2006, 67, 379-383.	0.5	103
23	Prostate Biopsy Strategies: Current State of the Art. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2, 213-222.	2.3	O
24	Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology, 2002, 60, 836-840.	0.5	118